

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

AUGUST 20, 2025

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, August 20, 2025, via webinar, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

Ghassan Al-Sabbagh, MD, Gastroenterologist/Hepatologist, Gastroenterology & Hepatology Consultants

W. Russell Laundon, PharmD, Pharmacist, Director of Pharmacy Integration, UNC Health Care

Phil Seats, RPh, Retired Pharmacist

Timothy Ashley MD, MPH Internal Medicine and Pediatrics, Duke Primary Care, Regional Director

Garland Moeller MD, Rheumatologist, CarolinaEast Internal Medicine

Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center

Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians

MEMBERS ABSENT:

David Konanc, MD, Neurologist, Raleigh Neurology Associates

PLAN & VENDOR STAFF:

Tom Friedman, Executive Director, State Health Plan

Caroline Smart, Deputy Executive Administrator, State Health Plan

Jenny Vogel, PharmD, Sr. Clinical Pharmacist, State Health Plan

Emma Turner, Chief Economist, State Health Plan

Sonya Dunn, Director Integrated Health Management, State Health Plan

Renée Jarnigan, RPh, Clinical Advisor, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest Statement

The Chairperson requested that the P&T Committee members review the agenda, which was distributed prior to the meeting, and to disclose any actual or potential conflicts of interest with any item on the agenda. No conflicts of interest were noted.

Old Business

The Chairperson asked the P&T Committee members to review the May 14, 2025 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

Executive Director Update

Mr. Friedman provided members of the committee with a brief executive director update.

Formulary Updates

Dr. Vogel and Ms. Jarnigan began by presenting CVS Caremark's Quarterly Formulary Updates, effective October 1, 2025. This included additions to the formulary, utilization management criteria, product exclusions, and tier movements.

Dr. Vogel and Ms. Jarnigan identified five new molecular entities that were being removed from CVS's New-to-Market block and would be available as covered products, along with any utilization management policies that went along with the new products. The new molecular entities proposed for addition to the formulary are as follows: FRUZAQLA, NEMLUVIO, SYFOVRE, OJJAARA, and EMBLAVEO.

Much discussion ensued around FRUZAQLA and EMBLAVEO. At the request of committee members these two medications will not be approved during today's meeting, but instead will be reevaluated and voted on during the next P&T Committee Meeting.

The Committee approved the formulary additions of NEMLUVIO, SYFOVRE and OJJAARA along with the proposed utilization management, including Specialty Guideline Management (SGM) and Specialty QL for OJJAARA and NEMLUVIO. SGM was approved for SYFOVRE.

Ms. Jarnigan then presented the SGM update on RA products.

There was no opposition from the Committee members, so the SGM update for RA products was approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medically necessary reason to allow coverage of a formulary excluded drug.

Ms. Jarnigan reviewed that VYVANSE will be excluded from the formulary starting on the effective date. This medication has therapeutic alternatives that are covered as preferred products on the Plan's

custom formulary. Dr. Vogel provided historical context to utilization of this product and manufacturer related inventory challenges.

There was no opposition from the Committee members, so the formulary exclusion was approved as presented.

Ms. Jarnigan then identified one branded product, NAFTIN, which will have a change in tier from preferred to non-preferred status.

There was no opposition from the Committee members, so the tier change was approved as presented.

Adjourn

The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on October 22, 2025 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 7:35 P.M. (EST)

Jenny Vogel, Chair